Drugs / micronized flavonoid fraction
micronized flavonoid fraction
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05772351 | Nov 2021 → Dec 2022 | hemorrhoid | Center of Endourology "Endocenter" | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | micronized flavonoid fraction | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05772351 ↗ |
| Known as | Detralex | “All participants are randomly divided into 2 groups: the first one gets a tablet with 1000 mg MFF (Detralex®), the second one gets a tablet containing starch per os 14 days...” NCT05772351 ↗ |
| Known as | MFF | “All participants are randomly divided into 2 groups: the first one gets a tablet with 1000 mg MFF (Detralex®), the second one gets a tablet containing starch per os 14 days...” NCT05772351 ↗ |
| Known as | MMF | “Aim: To assess the efficiency of the micro-flavonoid fraction (MMF) administration prior to anorectal surgery with spinal anesthesia on postoperative pain severity reduction.” NCT05772351 ↗ |
| Route | Oral | “All participants are randomly divided into 2 groups: the first one gets a tablet with 1000 mg MFF (Detralex®), the second one gets a tablet containing starch per os 14 days...” NCT05772351 ↗ |